Search Within

Jordan Chervin

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
Groups
  1. Adult Leukemia (5)
  2. Center for Hematologic Malignancies (5)
  3. Department of Medicine (5)
  4. Executive Committee, Center for Hematologic Malignancies (5)
  5. GSK Faculty (5)
  6. Hematologic Malignancies, Division of (5)

More Groups

People
  1. Eytan Stein (5)
  2. Ross Levine (5)
  3. Andrew Dunbar (3)
  4. Sheng Cai (3)
  5. Aaron Goldberg (1)
  6. Aaron Stonestrom (1)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2020 (1)
  5. 2018 (1)
Publications
  1. Blood (3)
  2. Blood Advances (2)
Publishers
  1. American Society of Hematology (5)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
    Journal Article

    Cai, S. F.; Huang, Y.; Lance, J. R.; Mao, H. C.; Dunbar, A. J.; McNulty, S. N.; Druley, T.; Li, Y.; Baer, M. R.; Stock, W.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
    Journal Article

    McCarter, J. G. W.; Nemirovsky, D.; Famulare, C. A.; Farnoud, N.; Mohanty, A. S.; Stone-Molloy, Z. S.; Chervin, J.; Ball, B. J.; Epstein-Peterson, Z. D.; Arcila, M. E.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial
    Meeting Abstract

    Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Enasidenib is highly active in previously untreated IDH2 mutant AML: Early results from the Beat AML Master Trial
    Meeting Abstract

    Stein, E. M.; Shoben, A.; Borate, U.; Baer, M. R.; Stock, W.; Patel, P. A.; Kovacsovics, T.; Blum, W.; Vergilio, J. A.; Heerema, N. A.; more...
    Blood (2018)

    Fulltext@MSK | Save